Few published studies by others have shown an inhibitory role of SEC23A in human cancer progression thus its expression is correlated with favorable clinical outcomes including prostate cancer (Szczyrba et al., 2011), colorectal cancer (Li et al., 2016), melanoma (Sun et al., 2018, 2020), and breast cancer (Korpal et al., 2011). Here, SEC23A is linked to cancer.